Spring House, PA, United States of America

Jinquan Luo

USPTO Granted Patents = 51 (Patent Applications = 25)

CIPO Patents = 6 (Patent Applications = 11)

EPO Patents = 11 (Patent Applications = 30)

Average Co-Inventor Count = 8.9

ph-index = 10

Forward Citations = 254(Granted Patents)

Forward Citations (Not Self Cited) = 248(Oct 12, 2025)

Location History:

Berwyn, PA (US) (2011 - 2012)
Radnor, PA (US) (2013 - 2015)
Spring House, PA (US) (2013 - 2023)
Malvern, PA (US) (2009 - 2024)

Company Filing History:

43 out of 410

Janssen Biotech, Inc.

patents

4 out of 2,076

Janssen Pharmaceutica Nv

patents

2 out of 3

Biocerox Products B.v.

patents

4. 2 out of 159

Janssen Pharmaceuticals, Inc.

Centocor Ortho Biotech Inc.

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12460001 - Proteins comprising CD3 antigen binding domains and uses thereof (2025-11-04),

2. 12234280 - Anti-PHF-tau antibodies and uses thereof (2025-02-25),

3. 12161716 - Anti-IL-23 antibodies, compositions, methods and uses (2024-12-10),

4. 12084501 - Proteins comprising CD3 antigen binding domains and uses thereof (2024-09-10),

5. 12077585 - Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses (2024-09-03),

6. 12071466 - Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof (2024-08-27),

7. 11787875 - Materials and methods for improved single chain variable fragments (2023-10-17),

8. 11746161 - Antibodies that specifically bind PD-1 and methods of use (2023-09-05),

9. 11236155 - Antibodies to pyroglutamate amyloid-β and uses thereof (2022-02-01),

10. 11185584 - Anti-IL-23 antibodies, compositions, methods and uses (2021-11-30),

11. 10995149 - Antibodies that specifically bind PD-1 and methods of use (2021-05-04),

12. 10844122 - Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof (2020-11-24),

13. 10781246 - Compositions and methods for anti-staphylococcal biologic agents (2020-09-22),

14. 10759854 - Interferon alpha and omega antibody antagonists (2020-09-01),

15. 10633435 - Anti-PHF-tau antibodies and uses thereof (2020-04-28),

Title: **Innovative Contributions of Jinquan Luo in Antibody Development**

Introduction

Jinquan Luo, based in Spring House, Pennsylvania, is a prolific inventor with an impressive portfolio of 50 patents. His work primarily focuses on the development of monoclonal antibodies and their applications in treating and diagnosing various medical conditions, particularly tauopathies and inflammatory diseases.

Latest Patents

Among his latest inventions are two significant patents:

1. **Anti-PHF-tau antibodies and uses thereof** - This invention describes monoclonal antibodies and their antigen-binding fragments targeting tau proteins. It also encompasses nucleic acids encoding these antibodies and compositions that include them. Furthermore, it outlines methods for producing and utilizing these antibodies in the treatment and prevention of tauopathies, as well as their application for quantifying tau levels in biological samples.

2. **Anti-IL-23 antibodies, compositions, methods and uses** - This patent involves an anti-IL-23 antibody, along with isolated nucleic acids that encode these antibodies. Additionally, it includes vectors, host cells, transgenic animals or plants, and methods for their production and utilization, showing potential in diagnostic and therapeutic applications.

Career Highlights

Jinquan Luo has held significant roles in key biopharmaceutical companies, including Janssen Biotech, Inc. and Janssen Pharmaceutica NV. His contributions in these organizations have advanced the field of immunotherapy and reinforced the importance of innovative therapeutic strategies.

Collaborations

Throughout his career, Luo has collaborated with esteemed colleagues like Mark Hilary Cunningham and Raymond W Sweet. These collaborations have further strengthened his ability to innovate and develop impactful solutions in the healthcare sector.

Conclusion

Jinquan Luo remains a notable figure in the realm of biological sciences, particularly in antibody research. His extensive patent portfolio and collaborations highlight his ongoing contribution to advancements in medical therapies, making a significant impact on the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.